Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma.

Adjuvant radiotherapy Comprehensive genomic profiling Human papillomavirus infection Penile cancer Squamous-cell carcinoma

Journal

European urology oncology
ISSN: 2588-9311
Titre abrégé: Eur Urol Oncol
Pays: Netherlands
ID NLM: 101724904

Informations de publication

Date de publication:
10 2021
Historique:
received: 07 08 2020
revised: 20 10 2020
accepted: 30 10 2020
pubmed: 18 11 2020
medline: 2 2 2022
entrez: 17 11 2020
Statut: ppublish

Résumé

Data on the impact of human papillomavirus (HPV) infection status and outcomes for perioperative treatments for patients with lymph node-involved penile squamous-cell carcinoma (PSCC) are lacking. To analyze the benefit from perioperative radiotherapy (RT) for PSCC according to HPV infection status. In an international multicenter database of 1254 patients with PSCC who received inguinal lymph node dissection (ILND), 507 had suitable clinical information. ILND, with or without chemotherapy or RT for involved lymph nodes. Kaplan-Meier and restricted mean survival time (RMST) analyses for overall survival (OS) were performed for all patients and after propensity score-matching (PSM; n = 136), for which patient age, histology, type of penile surgical procedure, pathological tumor and nodal stage, ILND laterality, pelvic LND, and perioperative treatment were taken into account when assessing differences between HPV Patients with HPV Perioperative RT was more effective in the HPV We analyzed data from a large multicenter database for patients with penile cancer who had received inguinal lymph node dissection, with or without chemotherapy or radiotherapy. We found that for tumors positive for human papillomavirus (HPV), use of radiotherapy resulted in prolonged survival compared to HPV-negative tumors. On the basis of these results we are inspired to design studies on the use of radiotherapy in HPV-selected patients.

Sections du résumé

BACKGROUND
Data on the impact of human papillomavirus (HPV) infection status and outcomes for perioperative treatments for patients with lymph node-involved penile squamous-cell carcinoma (PSCC) are lacking.
OBJECTIVE
To analyze the benefit from perioperative radiotherapy (RT) for PSCC according to HPV infection status.
DESIGN, SETTING, AND PARTICIPANTS
In an international multicenter database of 1254 patients with PSCC who received inguinal lymph node dissection (ILND), 507 had suitable clinical information.
INTERVENTION
ILND, with or without chemotherapy or RT for involved lymph nodes.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
Kaplan-Meier and restricted mean survival time (RMST) analyses for overall survival (OS) were performed for all patients and after propensity score-matching (PSM; n = 136), for which patient age, histology, type of penile surgical procedure, pathological tumor and nodal stage, ILND laterality, pelvic LND, and perioperative treatment were taken into account when assessing differences between HPV
RESULTS AND LIMITATIONS
Patients with HPV
CONCLUSIONS
Perioperative RT was more effective in the HPV
PATIENT SUMMARY
We analyzed data from a large multicenter database for patients with penile cancer who had received inguinal lymph node dissection, with or without chemotherapy or radiotherapy. We found that for tumors positive for human papillomavirus (HPV), use of radiotherapy resulted in prolonged survival compared to HPV-negative tumors. On the basis of these results we are inspired to design studies on the use of radiotherapy in HPV-selected patients.

Identifiants

pubmed: 33199252
pii: S2588-9311(20)30176-0
doi: 10.1016/j.euo.2020.10.011
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

802-810

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Marco Bandini (M)

San Raffaele Hospital and Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Jeffrey S Ross (JS)

Foundation Medicine Inc., Cambridge, MA, USA; Upstate Medical University, Syracuse, NY, USA.

Yao Zhu (Y)

Fudan University Shanghai Cancer Center, Shanghai, China.

Ding-Wei Ye (DW)

Fudan University Shanghai Cancer Center, Shanghai, China.

Antonio A Ornellas (AA)

Hospital Mário Kröeff and Brazilian Cancer Institute, Rio de Janeiro, Brazil.

Nick Watkin (N)

St. George's University Hospitals NHS Foundation Trust, London, UK.

Benjamin A Ayres (BA)

St. George's University Hospitals NHS Foundation Trust, London, UK.

Oliver W Hakenberg (OW)

University Hospital Rostock, Rostock, Germany.

Axel Heidenreich (A)

Universitätsklinikum Köln, Köln, Germany.

Roberto Salvioni (R)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Mario Catanzaro (M)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Daniele Raggi (D)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Patrizia Giannatempo (P)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Laura Marandino (L)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Friederike Haidl (F)

Universitätsklinikum Köln, Köln, Germany.

Filippo Pederzoli (F)

San Raffaele Hospital and Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Alberto Briganti (A)

San Raffaele Hospital and Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Francesco Montorsi (F)

San Raffaele Hospital and Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Juan Chipollini (J)

Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Mounsif Azizi (M)

Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Gert De Meerleer (G)

University Hospitals Leuven, Leuven, Belgium.

Oscar R Brouwer (OR)

The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

G Daniel Grass (GD)

Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Peter A Johnstone (PA)

Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Maarten Albersen (M)

University Hospitals Leuven, Leuven, Belgium.

Philippe E Spiess (PE)

Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Electronic address: Philippe.Spiess@moffitt.org.

Andrea Necchi (A)

San Raffaele Hospital and Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: andrea.necchi@istitutotumori.mi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH